当前位置: 首页 >> 检索结果
190. Bifidobacterium breve BBG-001 in very preterm infants: a randomised controlled phase 3 trial.
作者: Kate Costeloe.;Pollyanna Hardy.;Edmund Juszczak.;Mark Wilks.;Michael R Millar.; .
来源: Lancet. 2016年387卷10019期649-660页
Probiotics may reduce necrotising enterocolitis and late-onset sepsis after preterm birth. However, there has been concern about the rigour and generalisability of some trials and there is no agreement about whether or not they should be used routinely. We aimed to test the effectiveness of the probiotic Bifidobacterium breve BBG-001 to reduce necrotising enterocolitis, late-onset sepsis, and death in preterm infants.
191. The medical response to multisite terrorist attacks in Paris.
作者: Martin Hirsch.;Pierre Carli.;Rémy Nizard.;Bruno Riou.;Barouyr Baroudjian.;Thierry Baubet.;Vibol Chhor.;Charlotte Chollet-Xemard.;Nicolas Dantchev.;Nadia Fleury.;Jean-Paul Fontaine.;Youri Yordanov.;Maurice Raphael.;Catherine Paugam Burtz.;Antoine Lafont.; .
来源: Lancet. 2015年386卷10012期2535-8页 194. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
作者: Andrea Wang-Gillam.;Chung-Pin Li.;György Bodoky.;Andrew Dean.;Yan-Shen Shan.;Gayle Jameson.;Teresa Macarulla.;Kyung-Hun Lee.;David Cunningham.;Jean F Blanc.;Richard A Hubner.;Chang-Fang Chiu.;Gilberto Schwartsmann.;Jens T Siveke.;Fadi Braiteh.;Victor Moyo.;Bruce Belanger.;Navreet Dhindsa.;Eliel Bayever.;Daniel D Von Hoff.;Li-Tzong Chen.; .
来源: Lancet. 2016年387卷10018期545-557页
Nanoliposomal irinotecan showed activity in a phase 2 study in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapies. We assessed the effect of nanoliposomal irinotecan alone or combined with fluorouracil and folinic acid in a phase 3 trial in this population.
196. Will Ebola change the game? Ten essential reforms before the next pandemic. The report of the Harvard-LSHTM Independent Panel on the Global Response to Ebola.
作者: Suerie Moon.;Devi Sridhar.;Muhammad A Pate.;Ashish K Jha.;Chelsea Clinton.;Sophie Delaunay.;Valnora Edwin.;Mosoka Fallah.;David P Fidler.;Laurie Garrett.;Eric Goosby.;Lawrence O Gostin.;David L Heymann.;Kelley Lee.;Gabriel M Leung.;J Stephen Morrison.;Jorge Saavedra.;Marcel Tanner.;Jennifer A Leigh.;Benjamin Hawkins.;Liana R Woskie.;Peter Piot.
来源: Lancet. 2015年386卷10009期2204-21页 199. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
作者: Matthew James Armstrong.;Piers Gaunt.;Guruprasad P Aithal.;Darren Barton.;Diana Hull.;Richard Parker.;Jonathan M Hazlehurst.;Kathy Guo.; .;George Abouda.;Mark A Aldersley.;Deborah Stocken.;Stephen C Gough.;Jeremy W Tomlinson.;Rachel M Brown.;Stefan G Hübscher.;Philip N Newsome.
来源: Lancet. 2016年387卷10019期679-690页
Glucagon-like peptide-1 (GLP-1) analogues reduce hepatic steatosis, concentrations of liver enzymes, and insulin resistance in murine models of fatty liver disease. These analogues are licensed for type 2 diabetes, but their efficacy in patients with non-alcoholic steatohepatitis is unknown. We assessed the safety and efficacy of the long-acting GLP-1 analogue, liraglutide, in patients with non-alcoholic steatohepatitis.
|